

HARMONi-GI3

If you are interested in the HARMONi-GI3 clinical study, please contact your doctor for more information.

Have you or someone you love been diagnosed with colorectal cancer (CRC) that has already spread (metastatic CRC)?



HARMONi-GI3 is a global phase 3 clinical study of ivonescimab* versus bevacizumab in combination with chemotherapy for patients that have not had prior treatment for metastatic colorectal cancer (CRC).

Randomized: Patients are randomly assigned into different treatment groups.

Double-blind: Neither patients nor doctors know which treatment will be assigned.



* Ivonescimab is an investigational drug that is being studied for its safety and effectiveness against the current established standard of care.

HARMONi-GI3



Learn more by visiting ClinicalTrials.gov (NCT07228832)


Or

Email medinfo@smmmtx.com



Summit Therapeutics and the Summit Therapeutics logo are trademarks of Summit Therapeutics Inc. Copyright 2025, Summit Therapeutics Inc. All Rights Reserved.

MAT-SMT112-0329 | Version 1.0 | 24 Nov 2025
Protocol Amendment 1 | 27 Aug 2025



HARMONi-GI3

Have You or Someone You Love Been Diagnosed with Metastatic Colorectal Cancer (CRC)?

If yes, there is a phase 3 clinical study called HARMONi-GI3 you may want to ask your doctor about.



What is the purpose of this clinical study?

- The purpose of this phase 3 clinical study is to determine whether the combination of ivonescimab with chemotherapy improves the length of time patients live without their cancer getting worse after starting treatment (PFS or progression-free survival) compared to bevacizumab combined with chemotherapy.

What is the clinical study drug, ivonescimab?

- Ivonescimab is an investigational treatment which works by blocking two separate targets in the body to decrease the cancer cells' ability to live, grow, and spread.

Are you eligible for this clinical study?

- You may be eligible if you have been diagnosed with metastatic CRC and have not received any prior treatment for CRC in the metastatic setting.
- Please talk with your doctor to determine if you are eligible.

If you are eligible, what is involved?

- Once enrolled in the clinical study, you will visit the clinic every two weeks for infusions (drug delivered directly to the bloodstream) that may continue up to 24 months.
- You will receive regular blood tests and scans of your tumor.
- You will be regularly asked about any side effects or safety concerns you have.

If you are in the clinical study, will you receive ivonescimab?

- You will be randomly assigned to one of two treatment groups.
- Half the patients will be assigned to receive ivonescimab and chemotherapy and the other half will receive bevacizumab and chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA).

HARMONi-GI3

